In the GSE109211 cohort, sorafenib non-response rates in patients with elevated ADM expression substantially exceeded those with low expression; in vitro and in vivo experiments demonstrated ADM knockdown markedly enhances sorafenib’s inhibitory effects on HCC cell proliferation. This evidence concerns the gene ADM and hepatocellular carcinoma.